Compare CAL & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAL | CCCC |
|---|---|---|
| Founded | 1878 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.0M | 404.7M |
| IPO Year | 1994 | 2020 |
| Metric | CAL | CCCC |
|---|---|---|
| Price | $12.45 | $2.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $17.00 | $13.33 |
| AVG Volume (30 Days) | 539.7K | ★ 1.9M |
| Earning Date | 09-09-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $85,513,000.00 | $35,947,000.00 |
| Revenue This Year | $3.87 | N/A |
| Revenue Next Year | $2.84 | N/A |
| P/E Ratio | $5.72 | ★ N/A |
| Revenue Growth | 0.46 | ★ 1.02 |
| 52 Week Low | $8.80 | $1.69 |
| 52 Week High | $15.04 | $5.17 |
| Indicator | CAL | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 31.02 |
| Support Level | $12.02 | $2.52 |
| Resistance Level | $14.20 | $3.91 |
| Average True Range (ATR) | 0.50 | 0.20 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 69.11 | 1.92 |
Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - Famous Footwear and Brand Portfolio. The Famous Footwear segment is comprised of its Famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. This segment is comprised of wholesale operations that designs, develops, sources, manufactures, markets and distributes branded, licensed and private-label footwear. Geographically, the company generates the majority of its revenue from Domestic operations.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.